Shay Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Shay Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-35,000	Closed	-$3.15M	–	633
2022 Q1	$3.15M	Buy	35,000 +20,000	+133%	+$1.85M	0.4%	29
2021 Q4	$1.68M	Buy	+15,000	New	+$1.81M	0.28%	61

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Shay Capital's XBI Position: Q1 2022 in Review

Shay Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 113,721 shares — an estimated $10.5M sold.

Shay Capital first reported a position in XBI in Q2 2021 and held it in 3 quarters. The position peaked at $12.7M in Q4 2021. 702 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

Shay Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
Shay Capital sold 113,721 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $10.5M.
Shay Capital first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and held it in 3 quarters.
Shay Capital's State Street SPDR S&P Biotech ETF position peaked at $12.7M in Q4 2021.
702 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Shay Capital's 13F filing for Q1 2022, filed 16 May 2022.